Revolutionizing Drug Development
Microphysiological Systems (MPS) are pioneering innovative in vitro platforms that replicate human organ functions, enhancing drug development and reducing reliance on animal testing. By mimicking human organ-level functions on a microfluidic platform, MPS provide unprecedented accuracy in disease modeling, drug discovery, and personalized medicine.
Objectives
Enhance Drug Testing Efficiency:
- Develop MPS models to accelerate drug testing by accurately simulating human responses, reducing the time and cost of bringing new therapies to market.
Improve Predictive Accuracy:
- Utilize MPS to enhance the reliability of preclinical results, ensuring better translatability of research to clinical outcomes by mimicking complex organ interactions.
Reduce Reliance on Animal Testing:
- Minimize animal use in research by providing ethical alternatives through MPS, supporting the principles of the 3Rs (Replacement, Reduction, and Refinement).
Support Personalized Medicine:
- Enable personalized treatment approaches by using patient-derived organoids to study individual drug responses, enhancing therapeutic effectiveness.
Key Features
Integrated Sensors:
- Utilizing advanced semiconductor integration, researchers will be able to collect time relevant, multiple biomarker high quality data.
Multi-Organ Interaction:
- Integrate multiple organ systems on a chip to study organ-organ interactions, providing insights into drug metabolism and efficacy.
Dynamic Microenvironment Control:
- Replicate physiological conditions through microfluidic systems that maintain cell viability and functionality, crucial for long-term studies.
High-Throughput Capabilities:
- Facilitate simultaneous testing of numerous drug candidates, significantly increasing experimental efficiency and data robustness.
Integration of AI and Data Analytics:
- Leverage AI to analyze complex datasets, enhancing predictive modeling and decision-making in drug development.
HUB Organoids
The acquisition of HUB Organoids Holding B.V. marks a significant advancement in our capabilities, allowing us to leverage their expertise in organoid technology. This integration enhances our MPS initiative, enabling more sophisticated and human-relevant testing methods. For more information about the HUB organoids portfolio, visit the page: The Life Science business of Merck KGaA, Darmstadt, Germany, to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio - HUB Organoids
Collaboration with imec
Strategic Partnership for Advanced MPS Development
Together with imec, a world-leading research and innovation hub in nanoelectronics and digital technologies, we are developing an advanced Microphysiological Systems (MPS) platform. This collaboration aims to create next-generation MPS-on-a-chip through a multipartner program, enhancing drug discovery and expediting candidate development. By combining our expertise in induced pluripotent stem cells and patient-derived organoids with imec’s cutting-edge semiconductor hardware, we aim to deliver unprecedented accuracy in simulating human body responses and generate high-quality training data for AI models, ultimately reducing reliance on animal testing. For further information about imec, please visit theirwebsite: Imec R&D, nano electronics and digital technologies
Contact Us
Interested in working together? Get in touch to learn more.